A vaccination protocol against murine Babesia microti infection, using glucan, a ,B-1,3-glucopyranose derivative of yeast cell walls, and glutaraldehyde-fixed infected erythrocytes was evaluated. BALB/c mice were immunized intravenously four times at 2-day intervals with 2 x 108 fixed infected erythrocytes with and without glucan (0.45 mg). The mice were challenged 2 weeks after the last immunization with 108 viable infected erythrocytes. Peak parasitemia was significantly reduced (8.9 ± 1.0%; P < 0.001) in glucan-immunized mice as compared with nonimmunized controls (41.2 ± 1.4%), glucan-treated controls (31.7 ± 2.5%; P < 0.05), or mice which received fixed infected erythrocytes without glucan (21.0 + 1.2%; P < 0.01). Humoral and cellular immunity to B. microti was evaluated before challenge by measuring antibody titers and splenocyte blastogenic responses to B. microti antigens. The in vitro cellular response was inversely correlated with mean peak parasitemia (P < 0.05). These observations demonstrate that glucan is an effective adjuvant in enhancing immunity to murine babesiosis.
Babesiosis is best known as a severe disease of domestic cattle which causes sizable economic losses. Attempts to control the spread of babesiosis in cattle have been made for a long time with variable success (19) . Most recently, available cultures of cattle Babesia (17) have made successful immunizations easier to achieve by using a culture-derived immunogen and saponin as an adjuvant (23) .
In addition to Babesia species affecting domestic large animals, Babesia microti, a parasite of wild rodents, is now known to be the etiological agent of clinical babesiosis in humans in the United States (8) . B. microti has been adapted to inbred laboratory mice, thereby providing a host-parasite model suitable for immunological and protection studies (22) .
The need for efficient adjuvants for the preparation of vaccines to intraerythrocytic parasites is an important component in the development of successful protection. We present here the results of a vaccine trial with glutaraldehydefixed infected erythrocytes (RBC) as antigen and glucan as an adjuvant in a B. microti-BALB/c mouse model. Glucan is a 3-1,3-glucopyranose derivative of yeast cell walls and a proven stimulant of the reticuloendothelial system. Glucan treatment has conferred nonspecific protection against a diverse group of viral (27) , fungal (26) , bacterial (16) , and parasitic (6) infections. Glucan has been used successfully as an adjuvant in trials with Venezuelan equine encephalitis virus (20) and Plasmodium berghei (13) and also has been used in combination with glutaraldehyde-treated tumor cells for induction of immunity to murine leukemia (1) .
MATERIALS AND METHODS
B. microt and mouse strains. The human-derived Peabody strain of B. microti was supplied by Mary Ruebush of the Bowman-Gray School of Medicine, Winston-Salem, N.C., and maintained in our laboratory by blood passage in BALB/c mice. For these trials, male BALB/c mice weighing 18 to 25 g each were used as donors of the antigen preparation and for the vaccine trials.
Preparation of inoculum. Glucan was prepared by a modification of the technique of Hassid and co-workers (12) , resulting in a sterile suspension of glucan in 5% dextrose. B. microti-infected RBC to be used as antigen were collected from mice with parasitemias of approximately 50%; the plasma and as much of the buffy coat as possible were removed, and the RBC were washed three times in sterile phosphate-buffered saline (pH 7.2). After the last wash, the cells were fixed in 0:25% glutaraldehyde for 15 min at room temperature, followed by three additional washes in sterile phosphate-buffered saline supplemented with penicillin and streptomycin. The fixed RBC were stored at 4°C in sterile 5% dextrose supplemented with antibiotics until used. Just before inoculation, the cells were washed twice in sterile 5% dextrose, counted, and reconstituted at the desired concentrations. Determination of immunization effectiveness. At 2 weeks after the last inoculation, 16 mice from each group (8 from each experiment) were sacrificed to determine specific antibody production, cellular response, and hematological values after the vaccine regimen. The serum was used for determination of antibodies specific for B. microti antigens by indirect immunofluorescence (3), using an anti-mouse immunoglobulin G conjugate (Cappel Laboratories). Hematocrits and leukocyte counts were made in a Coulter Counter (Model MCV-HCT; Coulter Electronics). Leukocyte differentials were made by conventional staining and microscopy.
Immediately after exsanguination, the spleen was removed aseptically and teased in RPMI 1640 medium supplemented with antibiotics to make a single-cell suspension. The splenocytes were washed three times, counted, resuspended in culture medium (RPMI 1640, 10 mM NaHCO3, 20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], 2.5% fetal calf serum, penicillin, streptomycin), and dispensed into sterile, flat-bottomed microtiter plates (Linbro) at 7.5 x 104 splenocytes per well. Antigen-specific responses were measured by adding 106 washed IRBC (45 to 55% parasitemia) per well; an equal number of normal mouse RBC were used as the antigen control (25) . Mitogens used to assess splenocyte function were phytohemagglutinin P (PHA; Sigma Chemical Co.), concanavalin A (ConA; GIBCO Laboratories), and Escherichia coli lipopolysaccharide (LPS) 0111-B4 (Westphal preparation; Difco). PHA was used at final well concentrations of 1:200, ConA was used at 5 ,ug/ ml, and LPS was used at 20 ,ug/ml. The cultures were incubated at 37°C in a 5% CO2 atmosphere and harvested at % h after having been pulsed 18 to 24 h earlier with 1 ,uCi of [3H]thymidine. Cultures were harvested by means of a multiple-sample automated cell harvester on glass filter paper disks. The filter paper disks were treated with methanol and Hyamine hydroxide (National Diagnostics) and then with 3 ml of scintillation fluid before being counted in a liquid scintillation counter (Mark III Beta; Tracor Analytic). Immunization of mice with a combination of G-IRBC and the glucan adjuvant affords a significant degree of protection against challenge with a large number (108) of B. microti-parasitized cells (Fig. 1) . Mean parasitemias in the mice of the G-IRBC group were significantly different from the glucan and control groups from days 5 to 8 (P < 0.001) and also significantly different from the IRBC group on days 5 to 7 (P < 0.05). The highest parasitemia recorded for any individual mouse in the G-IRBC group was 14% on day 5. IRBC or glucan alone provided only slight protection as compared with the nonimmunized controls: P < 0.01 (days 6 and 7) and P < 0.05 (days 6 through 10), respectively.
Predictors of protection against challenge. Regression analysis showed a significant (P < 0.05) inverse relationship between mean splenocyte response to the specific antigen (Table 1 ) and the highest parasitemia recorded after challenge for the mice of the same group (Fig. 1) ; that is, an increase in the [3H]thymidine uptake (DPM) in the sacrificed mice was associated with a decrease in the parasitemia in the remaining mice from the same group which were subsequently challenged. The same analysis showed a similar inverse relationship between the mean stimula- Glucan treatment, antigen immunization, and glucan and antigen combined resulted in increases in the numbers of cells in the spleen, with a significant increase (P < 0.05) in the mice from the G-IRBC group. A decrease in hematocrit occurred in all of the treated mice (Table 2) . Leukocyte counts were within normal limits. Differentials were also within normal limits; however, slight monocytosis, defined as 10 to 12% of the differential, was seen in 32% of the glucan-treated mice and in 37% of mice from the G-IRBC group. Reticulocytosis (5 to 12%) was seen in all treated mice.
DISCUSSION
Immunization of mice with a combination of glutaraldehyde-fixed, Babesia-infected RBC and glucan as an adjuvant affords a significant degree of protection against challenge with a large number of viable parasites (108 per mouse). A deliberately high challenge dose was used, since mortality of the experimental animal in this B. microti mouse model is not a criterion that can be used in the measurement of protection (22) . This immunization trial also provided evidence that prechallenge antibody and cellular immunity measurements can predict the existence of a protective effect against infection with B. microti.
Mean thymidine uptake (DPM) and mean stimulation indices showed specific stimulation The degree of protection may be indicated by the greater antigen-specific responses obtained in the mice from the G-IRBC group when compared to the mice from the IRBC group, as evidenced by the lower mean parasitemias in the mice from the G-IRBC group. However, antibody titers were not a good indicator of the degree of protection, since mice from both the G-IRBC and IRBC groups developed similar mean titers despite the differences seen in the mean parasitemias.
Blastogenic responses to nonspecific mitogens showed no obvious functional abnormalities, except for a significant decrease in responsiveness to PHA in the splenocytes from mice of the G-IRBC group and a significantly increased response to ConA in glucan-treated mice. Cook et al. (7), using two glucan injection protocols and different time intervals between glucan injection and sacrifice, showed varied effects of glucan on murine splenocyte responses to ConA and LPS.
Unlike BCG and Propionibacterium acnes, which induce a nonspecific protective effect against challenge with low doses ofB. microti (4, 5) , glucan treatment alone had only a slight protective effect against subsequent challenge.
Intravenous or intraperitoneal pretreatment with live BCG (4) and formalinized Propionibacterium acnes (5) resulted in negligible parasitemias after challenge with B. microti. In both instances, a nonspecific, antibody-independent soluble mediator was thought to be responsible for the intraerythrocytic death of the parasites. Although our timing factors, dosages, and regimens of pretreatment were different, it appears that glucan by itself does not protect against B. microti as do both BCG and Propionibacterium acnes.
Evidence is now accumulating to show that glucan has diverse in vivo effects and possible modes of action. Glucan administration to mice results in increased granulocyte and macrophage production in the spleen and other sites (2) , and this may account for the increased number of nucleated cells in the spleens of the treated mice. Chemically related Pl --3 glucans have been shown to alter the induction of cytotoxic T lymphocytes specific for allogeneic tumors both in vivo (10) and in vitro (11) .
, (1) (2) (3) Glucans have also been shown to activate the alternative complement pathway, resulting in an increased C3 consumption (9) . This is a potentially relevant activity, since recent studies have shown that C3 and C3b receptors are necessary for in vivo development of B. rodhaini infection in rats (15) . Although depletion of C3 levels in rats to below 5% of the normal levels was needed to delay the onset of parasitemia, it may be that enough C3 is consumed to retard parasite penetration of the RBC, thus rendering the organisms more vulnerable to other protective mechanisms. The in vivo effect of glucan on complement, if any, cannot be its only mechanism of adjuvanticity, since complement is not required for infection of either human or rodent RBC with Plasmodium (24); however, glucan was an effective adjuvant in a rodent-P. berghei vaccine (13) .
Limited clinical trials in cancer patients have shown that glucan is relatively nontoxic, occasionally producing temporary fever and local tenderness at the site and time of the injection (18) . The well-defined chemical structure of glucan, its lack of obvious toxicity, and the possibility of diverse and broad-spectrum adjuvant effects make this fungal polysaccharide of interest for further study.
